世界の腎臓がん治療薬市場は、2024年には66.8億米ドルと評価されており、2035年までに139.2億米ドルに達すると予想されており、予測期間（2024年〜2035年）の年平均成長率（CAGR）は6.9％です。世界的に急速に成長している腎臓がんは、製薬業界に対して、資源集約型のパイプライン開発や標的療法の迅速承認を通じて努力を強化することを求めています。腎細胞がん（RCC）が全体の約85〜90％を占める中、症例数の増加により腫瘍学的治療の競争環境はますます複雑になっています。これに伴い、先進的な免疫腫瘍学薬剤やチロシンキナーゼ阻害薬は、従来の化学療法に代わって、精密医療やバイオマーカーに基づく治療の中で導入が進んでいます。
世界の関係者にとっては、規制手続きや患者アクセスプログラムを通じて商業的な実現可能性を確保することが複雑です。各国政府は医療費抑制を目指す一方で、患者は最新の治療を求めており、製薬メーカーは価格戦略や価値に基づくケアモデルの再検討を迫られています。また、免疫チェックポイント阻害薬とVEGF標的療法の組み合わせなど、多剤併用レジメンによる寿命延長効果への理解も高まっており、このシフトによりバイオテクノロジー企業と多国籍製薬大手の長期的な協力の余地が広がっています。
製薬メーカーは臨床試験に多額の投資を行い、適応型試験デザインにより承認を迅速化しています。転移性RCCの第一選択治療薬は需要の増加が期待され、既存薬の適応拡大も市場を活発にしています。腫瘍医は患者中心の治療方針を推奨し始めており、腎臓がん治療薬市場は、革新性、アクセス可能性、長期的な治療持続性を特徴として変革を続けています。
腎臓がんの発症率の増加により、腎臓がん治療薬の需要は非常に高まっています。特にRCCの増加は先進的治療薬の需要を押し上げています。加えて、生活習慣の変化や高齢化、診断精度の向上も治療量の増加を後押ししています。製薬企業は、臨床パイプラインの拡充と新薬の迅速な投入を迫られています。
免疫腫瘍学と併用療法は、腎臓悪性腫瘍の治療パラダイムを改革しています。免疫チェックポイント阻害剤とVEGF標的療法の併用は、腎臓中心治療の現代的基盤となっています。全生存期間の延長と低毒性により、腫瘍医は第一選択治療として併用療法を勧める傾向が強まります。
一方、薬剤開発コストや規制上の障壁は市場投入のスピードを妨げる要因となっています。長期的な承認プロセスや高額な研究開発費用、費用対効果の証明が一部地域で新規治療薬導入を遅らせており、小規模バイオ企業には大きな制約となっています。
患者支援プログラムや価値に基づく医療へのシフトにより、採用は加速しています。政府や製薬会社は、補助金制度や償還制度、患者支援プログラムを拡充し、治療へのアクセスを向上させています。これにより、特に新興市場で商業的採用が進むと期待されています。
個別化治療のパイプライン拡大は、成長の魅力的な機会を提供しています。ドライバー薬や精密医療の重要性が高まることで、患者の遺伝情報に基づく個別化治療レジメンが腎臓がん治療に革命的な可能性をもたらしています。パイプラインの強化は、製薬企業にとって競争優位性をもたらします。
腎細胞がん（RCC）は、世界的に最も一般的な腎臓がんであり、治療市場で最大のシェアを占めています。VEGF阻害剤、チェックポイント阻害剤、チロシンキナーゼ阻害剤の強力なパイプラインにより、治療成果は大きく改善されています。さらに、臨床試験によりRCCの転移例や再発例への適応拡大が進められており、市場の成長を支えています。
移行上皮がんは、希少ですが臨床研究が進展しており、標的療法や免疫療法による治療法が注目されています。今後もこのサブタイプ向けの臨床投資は拡大すると見込まれます。
ウィルムス腫瘍は小児がんの主要なタイプであり、政府主導の研究プログラムや低毒性治療の導入により、市場は安定しています。国際的な協力により、薬剤アクセスも改善されています。
腎肉腫は希少腎臓がんの一種ですが、希少疾患薬の優遇措置により、臨床開発が活発化しています。個別化治療の進展もあり、小規模ながら高付加価値の市場機会があります。
世界の腎臓がん治療薬市場は、2024年の66.8億米ドルから2035年に139.2億米ドルに成長すると予測され、CAGRは6.9％です。成長の主な要因は、RCCの増加、免疫腫瘍学療法の採用、革新的治療へのアクセス拡大です。
北アメリカが市場をリードしており、臨床研究、薬剤パイプライン、償還制度が強みです。ヨーロッパは規制フレームワークと精密医療の導入で続き、アジア太平洋地域は最も高い成長率を示しています。
目次
Chapter 1. Market Snapshot
1.1. Market Definition & Report Overview
1.2. Market Segmentation
1.3. Key Takeaways
1.3.1. Top Investment Pockets
1.3.2. Top Winning Strategies
1.3.3. Market Indicators Analysis
1.3.4. Top Impacting Factors
1.4. Application Ecosystem Analysis
1.4.1. 360’ Analysis
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Market Attractiveness Analysis (top leader’s point of view on the market)
2.5. Key Findings
Chapter 3. Research Methodology
3.1. Research Objective
3.2. Supply Side Analysis
3.2.1. Primary Research
3.2.2. Secondary Research
3.3. Demand Side Analysis
3.3.1. Primary Research
3.3.2. Secondary Research
3.4. Forecasting Models
3.4.1. Assumptions
3.4.2. Forecasts Parameters
3.5. Competitive breakdown
3.5.1. Market Positioning
3.5.2. Competitive Strength
3.6. Scope of the Study
3.6.1. Research Assumption
3.6.2. Inclusion & Exclusion
3.6.3. Limitations
Chapter 4. Industry Landscape
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Porter’s 5 Forces Model
4.2.1. Bargaining Power of Buyer
4.2.2. Bargaining Power of Supplier
4.2.3. Threat of New Entrants
4.2.4. Threat of Substitutes
4.2.5. Competitive Rivalry
4.3. Value Chain Analysis
4.4. PESTEL Analysis
4.5. Pricing Analysis and Trends
4.6. Key growth factors and trends analysis
4.7. Market Share Analysis (2024)
4.8. Top Winning Strategies (2024)
4.9. Trade Data Analysis (Import Export)
4.10. Regulatory Guidelines
4.11. Historical Data Analysis
4.12. Analyst Recommendation & Conclusion
Chapter 5. Global Kidney Cancer Drugs Market Size & Forecasts by Type 2024-2035
5.1. Market Overview
5.1.1. Market Size and Forecast By Type 2024-2035
5.2. Renal Cell Carcinoma (RCC)
5.2.1. Market definition, current market trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2024-2035
5.2.3. Market share analysis, by country, 2024-2035
5.3. Transitional Cell Cancer
5.3.1. Market definition, current market trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2024-2035
5.3.3. Market share analysis, by country, 2024-2035
5.4. Wilms Tumour
5.4.1. Market definition, current market trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2024-2035
5.4.3. Market share analysis, by country, 2024-2035
5.5. Renal Sarcoma
5.5.1. Market definition, current market trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2024-2035
5.5.3. Market share analysis, by country, 2024-2035
Chapter 6. Global Kidney Cancer Drugs Market Size & Forecasts by Therapy 2024-2035
6.1. Market Overview
6.1.1. Market Size and Forecast By Therapy 2024-2035
6.2. Targeted therapy
6.2.1. Market definition, current market trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2024-2035
6.2.3. Market share analysis, by country, 2024-2035
6.3. Immunotherapy
6.3.1. Market definition, current market trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2024-2035
6.3.3. Market share analysis, by country, 2024-2035
6.4. Chemotherapy
6.4.1. Market definition, current market trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2024-2035
6.4.3. Market share analysis, by country, 2024-2035
6.5. Other therapies
6.5.1. Market definition, current market trends, growth factors, and opportunities
6.5.2. Market size analysis, by region, 2024-2035
6.5.3. Market share analysis, by country, 2024-2035
Chapter 7. Global Kidney Cancer Drugs Market Size & Forecasts by Drug Class 2024-2035
7.1. Market Overview
7.1.1. Market Size and Forecast By Drug Class 2024-2035
7.2. Angiogenesis inhibitors
7.2.1. Market definition, current market trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2024-2035
7.2.3. Market share analysis, by country, 2024-2035
7.3. Monoclonal antibodies
7.3.1. Market definition, current market trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2024-2035
7.3.3. Market share analysis, by country, 2024-2035
7.4. mTOR inhibitors
7.4.1. Market definition, current market trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2024-2035
7.4.3. Market share analysis, by country, 2024-2035
7.5. Cytokine immunotherapy (IL-2)
7.5.1. Market definition, current market trends, growth factors, and opportunities
7.5.2. Market size analysis, by region, 2024-2035
7.5.3. Market share analysis, by country, 2024-2035
7.6. Other drug classes
7.6.1. Market definition, current market trends, growth factors, and opportunities
7.6.2. Market size analysis, by region, 2024-2035
7.6.3. Market share analysis, by country, 2024-2035
Chapter 8. Global Kidney Cancer Drugs Market Size & Forecasts by Route of Administration 2024-2035
8.1. Market Overview
8.1.1. Market Size and Forecast By Route of Administration 2024-2035
8.2. Oral
8.2.1. Market definition, current market trends, growth factors, and opportunities
8.2.2. Market size analysis, by region, 2024-2035
8.2.3. Market share analysis, by country, 2024-2035
8.3. Intravenous
8.3.1. Market definition, current market trends, growth factors, and opportunities
8.3.2. Market size analysis, by region, 2024-2035
8.3.3. Market share analysis, by country, 2024-2035
8.4. Subcutaneous
8.4.1. Market definition, current market trends, growth factors, and opportunities
8.4.2. Market size analysis, by region, 2024-2035
8.4.3. Market share analysis, by country, 2024-2035
Chapter 9. Global Kidney Cancer Drugs Market Size & Forecasts by End Use 2024-2035
9.1. Market Overview
9.1.1. Market Size and Forecast By End Use 2024-2035
9.2. Hospital Pharmacies
9.2.1. Market definition, current market trends, growth factors, and opportunities
9.2.2. Market size analysis, by region, 2024-2035
9.2.3. Market share analysis, by country, 2024-2035
9.3. Retail Pharmacies
9.3.1. Market definition, current market trends, growth factors, and opportunities
9.3.2. Market size analysis, by region, 2024-2035
9.3.3. Market share analysis, by country, 2024-2035
9.4. Other
9.4.1. Market definition, current market trends, growth factors, and opportunities
9.4.2. Market size analysis, by region, 2024-2035
9.4.3. Market share analysis, by country, 2024-2035
Chapter 10. Global Kidney Cancer Drugs Market Size & Forecasts by Region 2024-2035
10.1. Regional Overview 2024-2035
10.2. Top Leading and Emerging Nations
10.3. North America Kidney Cancer Drugs Market
10.3.1. U.S. Kidney Cancer Drugs Market
10.3.1.1. Type breakdown size & forecasts, 2024-2035
10.3.1.2. Therapy breakdown size & forecasts, 2024-2035
10.3.1.3. Drug Class breakdown size & forecasts, 2024-2035
10.3.1.4. Route of Administration breakdown size & forecasts, 2024-2035
10.3.1.5. End Use breakdown size & forecasts, 2024-2035
10.3.2. Canada Kidney Cancer Drugs Market
10.3.2.1. Type breakdown size & forecasts, 2024-2035
10.3.2.2. Therapy breakdown size & forecasts, 2024-2035
10.3.2.3. Drug Class breakdown size & forecasts, 2024-2035
10.3.2.4. Route of Administration breakdown size & forecasts, 2024-2035
10.3.2.5. End Use breakdown size & forecasts, 2024-2035
10.3.3. Mexico Kidney Cancer Drugs Market
10.3.3.1. Type breakdown size & forecasts, 2024-2035
10.3.3.2. Therapy breakdown size & forecasts, 2024-2035
10.3.3.3. Drug Class breakdown size & forecasts, 2024-2035
10.3.3.4. Route of Administration breakdown size & forecasts, 2024-2035
10.3.3.5. End Use breakdown size & forecasts, 2024-2035
10.3.3.6.
10.4. Europe Kidney Cancer Drugs Market
10.4.1. UK Kidney Cancer Drugs Market
10.4.1.1. Type breakdown size & forecasts, 2024-2035
10.4.1.2. Therapy breakdown size & forecasts, 2024-2035
10.4.1.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.1.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.1.5. End Use breakdown size & forecasts, 2024-2035
10.4.2. Germany Kidney Cancer Drugs Market
10.4.2.1. Type breakdown size & forecasts, 2024-2035
10.4.2.2. Therapy breakdown size & forecasts, 2024-2035
10.4.2.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.2.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.2.5. End Use breakdown size & forecasts, 2024-2035
10.4.3. France Kidney Cancer Drugs Market
10.4.3.1. Type breakdown size & forecasts, 2024-2035
10.4.3.2. Therapy breakdown size & forecasts, 2024-2035
10.4.3.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.3.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.3.5. End Use breakdown size & forecasts, 2024-2035
10.4.4. Spain Kidney Cancer Drugs Market
10.4.4.1. Type breakdown size & forecasts, 2024-2035
10.4.4.2. Therapy breakdown size & forecasts, 2024-2035
10.4.4.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.4.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.4.5. End Use breakdown size & forecasts, 2024-2035
10.4.5. Italy Kidney Cancer Drugs Market
10.4.5.1. Type breakdown size & forecasts, 2024-2035
10.4.5.2. Therapy breakdown size & forecasts, 2024-2035
10.4.5.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.5.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.5.5. End Use breakdown size & forecasts, 2024-2035
10.4.6. Rest of Europe Kidney Cancer Drugs Market
10.4.6.1. Type breakdown size & forecasts, 2024-2035
10.4.6.2. Therapy breakdown size & forecasts, 2024-2035
10.4.6.3. Drug Class breakdown size & forecasts, 2024-2035
10.4.6.4. Route of Administration breakdown size & forecasts, 2024-2035
10.4.6.5. End Use breakdown size & forecasts, 2024-2035
10.5. Asia Pacific Kidney Cancer Drugs Market
10.5.1. China Kidney Cancer Drugs Market
10.5.1.1. Type breakdown size & forecasts, 2024-2035
10.5.1.2. Therapy breakdown size & forecasts, 2024-2035
10.5.1.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.1.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.1.5. End Use breakdown size & forecasts, 2024-2035
10.5.2. India Kidney Cancer Drugs Market
10.5.2.1. Type breakdown size & forecasts, 2024-2035
10.5.2.2. Therapy breakdown size & forecasts, 2024-2035
10.5.2.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.2.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.2.5. End Use breakdown size & forecasts, 2024-2035
10.5.3. Japan Kidney Cancer Drugs Market
10.5.3.1. Type breakdown size & forecasts, 2024-2035
10.5.3.2. Therapy breakdown size & forecasts, 2024-2035
10.5.3.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.3.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.3.5. End Use breakdown size & forecasts, 2024-2035
10.5.4. Australia Kidney Cancer Drugs Market
10.5.4.1. Type breakdown size & forecasts, 2024-2035
10.5.4.2. Therapy breakdown size & forecasts, 2024-2035
10.5.4.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.4.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.4.5. End Use breakdown size & forecasts, 2024-2035
10.5.5. South Korea Kidney Cancer Drugs Market
10.5.5.1. Type breakdown size & forecasts, 2024-2035
10.5.5.2. Therapy breakdown size & forecasts, 2024-2035
10.5.5.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.5.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.5.5. End Use breakdown size & forecasts, 2024-2035
10.5.6. Rest of APAC Kidney Cancer Drugs Market
10.5.6.1. Type breakdown size & forecasts, 2024-2035
10.5.6.2. Therapy breakdown size & forecasts, 2024-2035
10.5.6.3. Drug Class breakdown size & forecasts, 2024-2035
10.5.6.4. Route of Administration breakdown size & forecasts, 2024-2035
10.5.6.5. End Use breakdown size & forecasts, 2024-2035
10.6. LAMEA Kidney Cancer Drugs Market
10.6.1. Brazil Kidney Cancer Drugs Market
10.6.1.1. Type breakdown size & forecasts, 2024-2035
10.6.1.2. Therapy breakdown size & forecasts, 2024-2035
10.6.1.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.1.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.1.5. End Use breakdown size & forecasts, 2024-2035
10.6.2. Argentina Kidney Cancer Drugs Market
10.6.2.1. Type breakdown size & forecasts, 2024-2035
10.6.2.2. Therapy breakdown size & forecasts, 2024-2035
10.6.2.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.2.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.2.5. End Use breakdown size & forecasts, 2024-2035
10.6.3. UAE Kidney Cancer Drugs Market
10.6.3.1. Type breakdown size & forecasts, 2024-2035
10.6.3.2. Therapy breakdown size & forecasts, 2024-2035
10.6.3.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.3.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.3.5. End Use breakdown size & forecasts, 2024-2035
10.6.4. Saudi Arabia (KSA Kidney Cancer Drugs Market
10.6.4.1. Type breakdown size & forecasts, 2024-2035
10.6.4.2. Therapy breakdown size & forecasts, 2024-2035
10.6.4.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.4.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.4.5. End Use breakdown size & forecasts, 2024-2035
10.6.5. Africa Kidney Cancer Drugs Market
10.6.5.1. Type breakdown size & forecasts, 2024-2035
10.6.5.2. Therapy breakdown size & forecasts, 2024-2035
10.6.5.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.5.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.5.5. End Use breakdown size & forecasts, 2024-2035
10.6.6. Rest of LAMEA Kidney Cancer Drugs Market
10.6.6.1. Type breakdown size & forecasts, 2024-2035
10.6.6.2. Therapy breakdown size & forecasts, 2024-2035
10.6.6.3. Drug Class breakdown size & forecasts, 2024-2035
10.6.6.4. Route of Administration breakdown size & forecasts, 2024-2035
10.6.6.5. End Use breakdown size & forecasts, 2024-2035
Chapter 11. Company Profiles
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Bristol Myers Squibb
11.2.1.1. Company Overview
11.2.1.2. Key Executives
11.2.1.3. Company Snapshot
11.2.1.4. Financial Performance (Subject to Data Availability)
11.2.1.5. Product/Services Port
11.2.1.6. Recent Development
11.2.1.7. Market Strategies
11.2.1.8. SWOT Analysis
11.2.2. Pfizer Inc.
11.2.3. Novartis AG
11.2.4. Merck & Co., Inc.
11.2.5. Roche Holding AG
11.2.6. Exelixis Inc.
11.2.7. Eisai Co., Ltd.
11.2.8. AstraZeneca PLC
11.2.9. Ipsen Pharma
11.2.10. Bayer AG
